Asia-Pacific ECMO Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Modality (Venoarterial ECMO, Venovenous ECMO, and Arteriovenous ECMO), Application (Respiratory and Cardiology), and Age Group (Adults, Pediatrics, and Neonates)

Asia-Pacific ECMO Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Modality (Venoarterial ECMO, Venovenous ECMO, and Arteriovenous ECMO), Application (Respiratory and Cardiology), and Age Group (Adults, Pediatrics, and Neonates)

The APAC ECMO market is expected to grow from US$ 110.85 million in 2022 to US$ 139.19 million by 2028. It is estimated to record a CAGR of 3.9% from 2022 to 2028.

Increasing Survival Rates with ECMO to Offer Opportunities for APAC ECMO Market During 2022–2028

The employment of ECMO for treating respiratory failure has been increasing in recent years, as treatments with ECMO show promising survival rates. Further, ECMO is recommended to treat patients suffering from acute respiratory distress syndrome (ADRS), primary graft dysfunction post lung transplant, and trauma to the lungs as it increases the survival rate of patients. Furthermore, ECMO increases the survival rate of patients affected by post-cardiac arrest regimen. A radical shift in adopting westernized lifestyles leads to various cardiac disorders. Thus, key players invest significantly in R&D, which results in improved treatment outcomes with ECMO with an increased survival rate. Therefore, the rising survival rate with ECMO use in various treatments is expected to provide lucrative opportunities for ECMO market in APAC during the forecast period.

APAC ECMO Market Overview

APAC is the fastest-growing regional ECMO market. China, India, and Japan are major contributors to the APAC ECMO market growth in the region. China dominated the market in 2022. According to an article by the National Center for Biotechnology Information (NCBI) titled Cardiovascular Health and Diseases in China, Cardiovascular Disease (CVD) accounted for ~47% and 44% of all deaths in rural and urban areas, respectively, in 2019. Two out of every five deaths occur due to CVD, and it is predicted that over 330 million patients suffer from CVD in China. The patients suffering from stroke, heart failure, coronary heart disease, pulmonary heart disease, rheumatic heart disease, atrial fibrillation, lower extremity artery disease, congenital heart disease, and hypertension were found to be 13 million, 11 million, 9 million, 5 million, 4.87 million, 2.50 million, 2 million, 45.30 million, and 245.00 million, respectively. Moreover, according to Statista data, the population aged above 60 years is estimated to grow from 17.4% in 2020 to 30% by 2040. Thus, China is facing the pressures of an aging population and the constant rise in the prevalence of metabolic risk factors. As a result, the CVD burden will continue to increase, setting new requirements for CVD prevention, treatment, and the allocation of medical resources in China. Furthermore, the penetration of international market players in the country is boosting the growth of the ECMO market. In July 2021, Xenios AG, a Fresenius Medical Care company, received approval from the National Medical Products Administration (NMPA) in China for the Xenios console and patient kits for ECMO therapy. Hence, the rising prevalence of CVD, the increasing geriatric population, and advancements by key players are expected to propel the ECMO market in China during the forecast period.

APAC ECMO Market Revenue and Forecast to 2028 (US$ Million)

APAC ECMO Market Segmentation

The APAC ECMO market is segmented based on modality, application, age group, and country.

Based on modality, the APAC ECMO market is segmented into venoarterial ECMO, venovenous ECMO, and arteriovenous ECMO. The venoarterial ECMO segment held the largest market share in 2022.

Based on application, the APAC ECMO market is bifurcated into respiratory and cardiology. The respiratory segment held a larger market share in 2022.

Based on age group, the APAC ECMO market is segmented into adults, pediatrics, and neonates. The adults segment held the largest market share in 2022.

Based on country, the APAC ECMO market has been categorized into China, India, Japan, South Korea, Australia, and the Rest of APAC. Our regional analysis states that China dominated the market in 2022.

ABIOMED Inc, Braile Biomedica, Eurosets S.R.L., Fresenius Medical Care AG & Co KGaA, Getinge AB, LivaNova Plc, Medtronic Plc, MicroPort Scientific Corporation, Nipro Medical Corporation, and Terumo Group are the leading companies operating in the APAC ECMO market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the APAC ECMO market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the APAC ECMO market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth APAC market trends and outlook coupled with the factors driving the ECMO market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.